Why Us
Key Differentiators
Therapeutic Competencies
Our Clients
Our Team
Solutions
Pricing and Contracting Strategies
Patient Support Services
Payer Marketing and Value Propositions
Innovative Contracting
Rare and Orphan Therapy Insights
Market Access Organizational Development
Advisory & Market Research
Platforms
RE Assist
RE Marketplace
News and Events
Social Media
Press Releases
Conferences
Gene Therapy Meeting – May 2023
Contact Us
Home
>
High Priced Drugs for Rare Disease: Leading US Payers Discuss Cost Concerns, Value-Based Contracts and ICER
News
Reset
<
>
June 14, 2020
Pink Sheet
High Priced Drugs for Rare Disease: Leading US Payers Discuss Cost Concerns, Value-Based Contracts and ICER
By Cathy Kelly
LOADING
LOADING
